AviClear
FDA-cleared 1726nm laser targeting sebaceous glands for acne
About This Treatment
AviClear is the world's first FDA-cleared acne-specific laser. Its 1726nm wavelength selectively targets lipids in sebaceous glands, suppressing sebum at the source. Unlike traditional acne treatments that "manage" symptoms, AviClear addresses the root cause.
3 treatments required; 90% of patients show improvement at 6 months, 92% maintain ≥50% clearance at 12 months. Emerging as an isotretinoin alternative.
Mechanism of Action
1726nm wavelength has high absorption coefficient for sebum (lipids) with relatively low absorption by melanin and water. This selectively heats sebaceous glands, inducing sebocyte apoptosis and sustained reduction in sebum production. Proprietary intelligent cooling system protects epidermis.
Indications
Expected Results
90% of patients show acne improvement at 6 months. 92% maintain ≥50% clearance at 12 months. Phase III trials confirm efficacy across mild, moderate, and severe acne. Long-lasting results reduce need for ongoing medication.
Clinical Evidence
Risks & Side Effects
Moderate treatment pain (reduced by cooling system). Transient redness/swelling (resolves within hours). Rare burns or blisters. Careful settings for darker skin (Fitzpatrick V-VI). Makeup allowed immediately after.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition